Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | DGKG | P49619 | 1/20 | 0.34 |
| ▸ | DGKB | Q9Y6T7 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 2/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862902 | 0.86 | HSP90AA1 (0.47) | GRM2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL4859850 | 0.86 | DCTPP1 (0.41) | BRD4EPHX2CREBBPDGKADGKG | |
| SCHEMBL4862736 | 0.82 | PDE1A (0.40) | ALDH1A1DCTPP1 | |
| SCHEMBL4762428 | 0.81 | MAPT (0.39) | MEN1KMT2AALDH1A1HPGDRAB9A | |
| SCHEMBL4762430 | 0.81 | MAPT (0.39) | MEN1KMT2AALDH1A1HPGDRAB9A | |
| SCHEMBL4864909 | 0.80 | ADORA2B (0.43) | CREBBPPKMALDH1A1 | |
| SCHEMBL4767578 | 0.79 | DCTPP1 (0.38) | DGKADGKGDGKBPKMMEN1 | |
| SCHEMBL4916172 | 0.78 | ADORA2B (0.45) | CREBBPALDH1A1 | |
| SCHEMBL4863582 | 0.76 | DCTPP1 (0.37) | BRD4CREBBPMEN1KMT2AALDH1A1 | |
| SCHEMBL4866995 | 0.76 | ERN1 (0.36) | BRD4EPHX2CCNT1CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | BRD4 1166/4885EPHX2 347/4885CREBBP 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.